AHA GUIDELINES Bundle (free trial)

Atrial Fibrillation 2023 Update

AHA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/387790

Contents of this Issue

Navigation

Page 81 of 131

82 Management Treatment required to decrease AF burden Heart failure? NO YES See sections 8.2 and 9 Shared decision- making Antiarrhythmic drugs (AADs) (See section 8.3.1) Catheter ablation (See section 8.4) Surgery (See section 8.6) Including discussion on timing of cardioversion if necessary (See section 8.2) Figure 20. Flowchart for Treatment Choices When Required to Decrease AF Burden * Younger with few comorbidities. Flowchart outlining overall strateg y and treatment options for patient with AF in whom rhythm-control therapy is required. Dofetilide Dronedarone Flecainide Propafenone (2a) Sotalol (2b) Antiarrhythmic drugs are ineffective (1) First-line therapy for selected patients* (1) First-line therapy for unselected patients (2a) Undergoing concomitant cardiac surgery (2a) Symptomatic, persistent, drug- refractory AF (2b)

Articles in this issue

Archives of this issue

view archives of AHA GUIDELINES Bundle (free trial) - Atrial Fibrillation 2023 Update